GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up

The non-obvious play is catalog rationalization before competitors force it on you — sellers sitting on high-velocity snack or confectionery SKUs should be modeling a 15-25% volume erosion scenario over 24 months as GLP-1 penetration compounds.

Advertising cost trends are the second-order hit: as incumbent food brands reallocate budgets toward GLP-1-friendly reformulations, CPCs in Health & Household and Grocery on Amazon will spike for the reformulated winners while legacy SKUs see conversion rate decay that erodes ACOS efficiency.

A $10M/year seller in food or beverage should run a catalog audit this Monday — tag every ASIN by caloric density and portion format, then map which SKUs are structurally misaligned with a population eating 20-30% less. Start repositioning ad spend toward protein-forward or functional variants NOW before the category bid wars inflate CPCs 30-40%.

This is the largest demand-side disruption to hit the food and beverage vertical since the low-fat craze of the 1990s, but with faster adoption velocity and measurable pharmacological enforcement behind it.

In the 2026 marketplace landscape, this compounds with Amazon's push into grocery and health — the platform has direct incentive to surface GLP-1-aligned products as a differentiation lever against Walmart+ and Target Circle, meaning algorithmic tailwinds will flow to reformulated SKUs faster than most sellers expect.

Brands that treat this as a labeling refresh rather than a fundamental catalog strategy reset will find themselves defending declining market share against insurgent DTC brands already built around GLP-1 consumer behavior.